The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The FDA has approved Merck’s Enflonasia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on data ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

WASHINGTON – The Food and Drug Administration has approved a new monoclonal antibody to protect infants from RSV. The ...

Merck scored a major win with FDA approval for Enflonsia, its fresh RSV-fighting antibody aimed at shielding infants. This ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...